Literature DB >> 28741377

Renal Cell Carcinoma: Alternative Nephron-Sparing Treatment Options for Small Renal Masses, a Systematic Review.

Fieke M Prins1, Linda G W Kerkmeijer1, Anne A Pronk2, Evert-Jan P A Vonken3, Richard P Meijer4, Axel Bex5, Maurits M Barendrecht6.   

Abstract

BACKGROUND: The standard treatment of T1 renal cell carcinoma (RCC) is (partial) nephrectomy. For patients where surgery is not the treatment of choice, for example in the elderly, in case of severe comorbidity, inoperability, or refusal of surgery, alternative treatment options are available. These treatment options include active surveillance (AS), radiofrequency ablation (RFA), cryoablation (CA), microwave ablation (MWA), or stereotactic body radiotherapy (SBRT). In the present overview, the efficacy, safety, and outcome of these different options are summarized, particularly focusing on recent developments.
MATERIALS AND METHODS: Databases of MEDLINE (through PubMed), EMBASE, and the Cochrane Library were systematically searched according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. The search was performed in December 2016, and included a search period from 2010 to 2016. The terms and synonyms used were renal cell carcinoma, active surveillance, radiofrequency ablation, microwave ablation, cryoablation and stereotactic body radiotherapy.
RESULTS: The database search identified 2806 records, in total 73 articles were included to assess the rationale and clinical evidence of alternative treatment modalities for small renal masses. The methodological quality of the included articles varied between level 2b and level 4.
CONCLUSION: Alternative treatment modalities, such as AS, RFA, CA, MWA, and SBRT, are treatment options especially for those patients who are unfit to undergo an invasive treatment. There are no randomized controlled trials available comparing surgery and less invasive modalities, leading to a low quality on the reported articles. A case-controlled registry might be an alternative to compare outcomes of noninvasive treatment modalities in the future.

Entities:  

Keywords:  active surveillance; cryoablation; focal therapy; microwave ablation; minimal invasive; radio frequency ablation; renal cancer; stereotactic body radiotherapy

Mesh:

Year:  2017        PMID: 28741377     DOI: 10.1089/end.2017.0382

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  13 in total

1.  Organ-sparing procedures in GU cancer: part 1-organ-sparing procedures in renal and adrenal tumors: a systematic review.

Authors:  Raouf Seyam; Mahmoud I Khalil; Mohamed H Kamel; Waleed M Altaweel; Rodney Davis; Nabil K Bissada
Journal:  Int Urol Nephrol       Date:  2019-01-08       Impact factor: 2.370

2.  Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study.

Authors:  Jean-Baptiste Beauval; Benoit Peyronnet; Thibaut Benoit; Bastien Cabarrou; Thomas Seisen; Mathieu Roumiguié; Benjamin Pradere; Zine-Eddine Khene; Quentin Manach; Gregory Verhoest; Mathieu Thoulouzan; Jerome Parra; Nicolas Doumerc; Romain Mathieu; Christophe Vaessen; Michel Soulié; Morgan Roupret; Karim Bensalah
Journal:  World J Urol       Date:  2018-02-09       Impact factor: 4.226

Review 3.  Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards.

Authors:  Julie Cronan; Sean Dariushnia; Zachary Bercu; Robert Mitchell Ermentrout; Bill Majdalany; Laura Findeiss; Janice Newsome; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

4.  Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis.

Authors:  Brigit M Aarts; Fernando M Gomez; Marta Lopez-Yurda; Rob F M Bevers; Joris Herndriks; Regina G H Beets-Tan; Axel Bex; Elisabeth G Klompenhouwer; Rutger W van der Meer
Journal:  Eur Radiol       Date:  2022-09-06       Impact factor: 7.034

5.  2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium: Meeting highlights.

Authors:  Anil Kapoor; Tamim Niazi; Krista Noonan; Ricardo A Rendon; Nimira Alimohamed; Wassim Kassouf; Alejandro Berlin; William Chu; Christian Kollmannsberger; Alan I So
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 2.052

6.  Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma.

Authors:  B M Aarts; W Prevoo; M A J Meier; A Bex; R G H Beets-Tan; E G Klompenhouwer; F M Gómez
Journal:  Cardiovasc Intervent Radiol       Date:  2020-02-12       Impact factor: 2.740

7.  Primary small cell carcinoma after renal transplant: A case report.

Authors:  Xueli Wang; Fenghua Wang; Yumei Liang; Wen Chen
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

8.  Diagnostic accuracy of contrast-enhanced ultrasound in the detection of small renal masses: A protocol of systematic review and meta-analysis.

Authors:  Jiang-Feng Wu; Chao Wu; Yun-Lai Wang; Zheng-Ping Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

Review 9.  Comparison of selective and main renal artery clamping in partial nephrectomy of renal cell cancer: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Lijin Zhang; Bin Wu; Zhenlei Zha; Hu Zhao; Jun Yuan; Yuefang Jiang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

10.  Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Jiang-Hong Luo; Xiong-Ying Jiang; Dong Chen; Wei-Dong Wang; Yao-Ting Chen; Jin-Hua Huang; Lin-Feng Xu
Journal:  Cancer Manag Res       Date:  2019-11-26       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.